secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inspire Medical Systems, Inc. (INSP)
CIK:        0001609550
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001609550-23-000061
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inspire Medical Q3 revenue $153.3M (+40% YoY); raises FY2023 guidance to $608-612M
--------------------------------------------------------------------------------

- Net loss narrowed to $8.5M ($0.29 per share) from $16.8M ($0.60) YoY.
- U.S. revenue $147.5M (+39%); OUS revenue $5.8M (+99%). Gross margin improved to 84.1%.
- Added 62 new U.S. implant centers (total 1,107) and 13 new sales territories (total 274).
- Surpassed 50,000 patients treated with Inspire therapy globally.
- FY2023 revenue guidance raised to $608-612M (49-50% growth); gross margin guidance maintained at 83-85%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609550/000160955023000061/0001609550-23-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609550/000160955023000061/insp-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001609550-23-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer